452 related articles for article (PubMed ID: 28027917)
1. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
2. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
3. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo.
Himaki T; Masui Y; Chono K; Daikoku T; Takemoto M; Haixia B; Okuda T; Suzuki H; Shiraki K
Antiviral Res; 2012 Feb; 93(2):301-304. PubMed ID: 22155691
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Chono K; Katsumata K; Suzuki H; Shiraki K
Antiviral Res; 2013 Feb; 97(2):154-60. PubMed ID: 23261844
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.
Katsumata K; Chono K; Kato K; Ohtsu Y; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2013 Mar; 57(3):1339-46. PubMed ID: 23274658
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
[TBL] [Abstract][Full Text] [Related]
8. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.
Katsumata K; Chono K; Sudo K; Shimizu Y; Kontani T; Suzuki H
Molecules; 2011 Aug; 16(9):7210-23. PubMed ID: 21869749
[TBL] [Abstract][Full Text] [Related]
9. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
Katsumata K; Chono K; Suzuki H
Biochem Pharmacol; 2018 Dec; 158():201-206. PubMed ID: 30365949
[TBL] [Abstract][Full Text] [Related]
10. Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
Shiraki K; Tan L; Daikoku T; Takemoto M; Sato N; Yoshida Y
Antiviral Res; 2020 Aug; 180():104829. PubMed ID: 32569704
[TBL] [Abstract][Full Text] [Related]
11. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
12. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis in mouse model.
Sasaki S; Miyazaki D; Haruki T; Yamamoto Y; Kandori M; Yakura K; Suzuki H; Inoue Y
Br J Ophthalmol; 2013 Apr; 97(4):498-503. PubMed ID: 23361434
[TBL] [Abstract][Full Text] [Related]
14. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
Shiraki K; Yasumoto S; Toyama N; Fukuda H
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs.
Marcelletti JF
Antiviral Res; 2002 Nov; 56(2):153-66. PubMed ID: 12367721
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
18. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
[TBL] [Abstract][Full Text] [Related]
19. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
